bleomycin

P1/2, N=18, Completed, Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Active, not recruiting --> Completed

A key management issue was the postoperative intensity of bleomycin, etoposide, and cisplatin (BEP) chemotherapy. The patient remains disease-free on follow-up. This case highlights the following two practical lessons: unusual ovarian germ cell tumors may remain unclassifiable despite integrated pathology, and adjuvant treatment decisions in stage I disease may depend not only on stage but also on staging adequacy and biologic uncertainty.

GSCA/GDSC-based drug sensitivity prediction suggested that high KIF7 expression was associated with increased predicted sensitivity to docetaxel and bleomycin, whereas no significant association was observed for I-BET-762. Additionally, it was associated with shaping the immune microenvironment. These findings highlight KIF7 as a potential prognostic biomarker and therapeutic target in ccRCC.

Both in vitro and in vivo experiments have validated the therapeutic efficacy and molecular mechanisms of IL-11-neutralizing antibodies in pulmonary fibrosis, offering promising insights for future anti-fibrotic drug development. Abbreviations: IL-11, Interleukin-11; IPF, Idiopathic pulmonary fibrosis; TGF-β, Transforming growth factor-β; NOX4, NADPH oxidase-4; SASP, Senescence-associated secretory phenotype; ECM, Extracellular matrix; α-SMA, α-smooth muscle actin; STAT3, Signal transducer and activator of transcription 3; ERK, Extracellular regulated protein kinases; AKT, Protein kinase B; BLM, Bleomycin; WT, Wild-type; KO, Knockout; qRT-PCR, Quantitative real-time polymerase chain reaction; WB, Western blot; hAb, Humanized antibody; mAb, Monoclonal antibody; FVC, Forced vital capacity; CTGF, Connective tissue growth factor; PDGFR-α, Platelet-derived growth factor receptor-α; TNF-α, Tumor necrosis factor-α; Nrf2, NFE2-related factor 2; EMT, Epithelial-mesenchymal transition; HE, Hematoxylin and eosin; PVDF, Polyvinylidene fluoride; GAPDH, Glyceraldehyde-3-phosphate dehydrogenase; siRNA, Small interfering RNA; IL-6, Interleukin-6; MEK, Mitogen-Activated Protein Kinase Kinase; TIME, TGF-β1/IL-11/MEK/ERK; HRP, Horseradish Peroxidase; MLG, Mouse lung fibroblast cell line MLg; NCBI, National Center for Biotechnology Information; Bcl2, BCL2 apoptosis regulator; Bax, BCL2 Associated X, apoptosis regulator; MSC, Mesenchymal Stem Cell; RSK, p90 Ribosomal S6 Kinase; KD, Dissociation Constant; Nin, Nintedanib; CTL, Control; Eto, Etoposide; SA-β-Gal, Senescence-Associated β-Galactosidase.

A 23-year-old woman with a history of two fertility-sparing surgeries and BEP (bleomycin, etoposide, cisplatin) chemotherapy for ovarian immature teratoma was followed up...Maintenance dienogest was subsequently given. At one-year follow-up, there was no evidence of disease progression; the patient maintained regular menstrual cycles and ovarian reserve was preserved (anti-Müllerian hormone (AMH) >2ng/mL), supporting a clinical diagnosis consistent with an endometriotic cyst. This case suggests that, in carefully selected patients with reassuring clinical, imaging, and laboratory findings and under close oncologic surveillance, a therapeutic trial of hormonal therapy may serve as an alternative to immediate surgical exploration for a newly developed adnexal mass after treatment for malignant ovarian tumors, especially when fertility preservation is a priority.

Moreover, we confirmed that PAF1c deficiency increases the cytotoxicity of several DNA-damaging agents, including hydroxyurea (HU), cisplatin (CDDP), methyl methanesulfonate (MMS), and bleomycin (BLM). Unexpectedly, PAF1c depletion confers tolerance specifically to topoisomerase inhibitors, such as camptothecin (CPT), etoposide (ETOP), and doxorubicin (DOX)...Collectively, our findings demonstrate that loss of PAF1c subunits not only promotes genomic instability through R-loop accumulation but also alters cellular responses to DNA-damaging agents, conferring resistance particularly to topoisomerase inhibitors. This study underscores the critical role of PAF1c in maintaining genome stability and provides a rationale for developing new therapeutic strategies in cancer treatment.

mRNA sequencing reveals an FASTIS-associated transcriptomic profile that overlaps between ACC and FASN inhibitors yet differs significantly from that of other mechanistically diverse TIS inducers, including bleomycin, alisertib, doxorubicin, and palbociclib. The FASTIS phenomenon is a therapeutic outcome through which cancer cells adapt to survive clinical-grade lipogenesis inhibitors. The cholesterol-addicted FASTIS fate can be rationally exploited as a collateral sensitivity in "one-two punch" senogenic-(immuno)senolytic strategies.

Furthermore, Nano-Brb reduced transforming growth factor-beta 1 (TGF-β1) expression and upregulated pulmonary sirtuin 3 (SIRT3) gene expression. The present results suggest that Nano-Brb enhanced the lung's architecture and functional performance by modulating inflammatory cytokines, oxidative stress, gene expression, and histopathological damage.

enterica cell extract significantly and selectively alters the expression of TOP, a critical cytosolic peptidase involved in the final stages of antigen processing. This targeted modulation likely serves as a mechanism for immune evasion by facilitating the destruction of immunogenic epitopes, thereby rendering infected cells less visible to the adaptive immune system.

Sirolimus was initiated but clinical deterioration continued within days, leading to the decision to provide interventional management. CONCLUSIONS Bleomycin sclerotherapy may be an effective and safe therapeutic option for propranolol resistance ulcerated infantile hemangiomas that fail conventional medical therapy. Early multidisciplinary evaluation and timely escalation to interventional treatment may help prevent progressive tissue destruction and improve functional and cosmetic outcomes in selected refractory cases.

Postpartum positron emission tomography/computed tomography demonstrated extensive supradiaphragmatic disease, and chemotherapy with doxorubicin, bleomycin, vinblastine, and dacarbazine was promptly initiated. The patient showed a favorable clinical and metabolic response, and the neonate demonstrated normal early postnatal development. This case highlights the importance of early recognition and multidisciplinary management of superior vena cava syndrome in pregnancy and raises the hypothesis that pregnancy-associated immunologic changes, including interleukin-6-mediated pathways, may contribute to accelerated disease progression.

P=N/A, N=0, Withdrawn, Istituto Ortopedico Rizzoli | N=30 --> 0 | Trial completion date: Aug 2029 --> Aug 2025 | Recruiting --> Withdrawn | Trial primary completion date: Aug 2028 --> Aug 2025